Regen BioPharma, Inc. (RGBP)
USD 0.05
(-12.78%)
USD 0.05
(-12.78%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 635.16 Thousand USD | -48.06% |
| 2022 | 1.22 Million USD | -57.18% |
| 2021 | 2.85 Million USD | 9.63% |
| 2020 | 2.6 Million USD | 21.76% |
| 2019 | 2.13 Million USD | 50.21% |
| 2018 | 1.42 Million USD | 236.96% |
| 2017 | 422.68 Thousand USD | 80.08% |
| 2016 | 234.72 Thousand USD | 27.48% |
| 2015 | 184.13 Thousand USD | 45.78% |
| 2014 | 126.3 Thousand USD | 208.96% |
| 2013 | -115.92 Thousand USD | -12459.26% |
| 2012 | -923.00 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 589.57 Thousand USD | -7.18% |
| 2024 Q2 | 615.66 Thousand USD | 4.42% |
| 2024 Q3 | 677.26 Thousand USD | 6.76% |
| 2023 Q2 | 523.89 Thousand USD | 11.26% |
| 2023 Q1 | 470.84 Thousand USD | -61.5% |
| 2023 FY | 635.16 Thousand USD | -48.06% |
| 2023 Q4 | 635.16 Thousand USD | 3.97% |
| 2023 Q3 | 610.89 Thousand USD | 16.61% |
| 2022 Q1 | 2.37 Million USD | -16.96% |
| 2022 Q2 | 2.76 Million USD | 16.55% |
| 2022 Q4 | 1.22 Million USD | -16.89% |
| 2022 FY | 1.22 Million USD | -57.18% |
| 2022 Q3 | 1.47 Million USD | -46.76% |
| 2021 Q3 | 2.19 Million USD | -13.96% |
| 2021 Q2 | 2.54 Million USD | -1.55% |
| 2021 Q1 | 2.58 Million USD | -0.7% |
| 2021 Q4 | 2.85 Million USD | 30.34% |
| 2021 FY | 2.85 Million USD | 9.63% |
| 2020 FY | 2.6 Million USD | 21.76% |
| 2020 Q1 | 2.2 Million USD | 3.26% |
| 2020 Q2 | 2.39 Million USD | 8.58% |
| 2020 Q3 | 2.53 Million USD | 5.63% |
| 2020 Q4 | 2.6 Million USD | 2.81% |
| 2019 FY | 2.13 Million USD | 50.21% |
| 2019 Q3 | 1.92 Million USD | 4.95% |
| 2019 Q2 | 1.83 Million USD | 14.42% |
| 2019 Q4 | 2.13 Million USD | 11.36% |
| 2019 Q1 | 1.59 Million USD | 12.33% |
| 2018 FY | 1.42 Million USD | 236.96% |
| 2018 Q4 | 1.42 Million USD | 21.62% |
| 2018 Q3 | 1.17 Million USD | 13.56% |
| 2018 Q1 | 674.6 Thousand USD | 59.6% |
| 2018 Q2 | 1.03 Million USD | 52.86% |
| 2017 FY | 422.68 Thousand USD | 80.08% |
| 2017 Q4 | 422.68 Thousand USD | 340.87% |
| 2017 Q3 | 95.87 Thousand USD | -58.26% |
| 2017 Q1 | 25.12 Thousand USD | -89.3% |
| 2017 Q2 | 229.69 Thousand USD | 814.33% |
| 2016 Q2 | 180.32 Thousand USD | 38712.63% |
| 2016 FY | 234.72 Thousand USD | 27.48% |
| 2016 Q1 | -467.00 USD | -100.25% |
| 2016 Q4 | 234.72 Thousand USD | 1.25% |
| 2016 Q3 | 231.83 Thousand USD | 28.57% |
| 2015 Q4 | 184.13 Thousand USD | 275.65% |
| 2015 Q2 | -388.22 Thousand USD | -253.89% |
| 2015 Q1 | 252.27 Thousand USD | 99.73% |
| 2015 Q3 | -104.83 Thousand USD | 73.0% |
| 2015 FY | 184.13 Thousand USD | 45.78% |
| 2014 Q1 | -267.81 Thousand USD | -131.03% |
| 2014 Q2 | -122.78 Thousand USD | 54.15% |
| 2014 Q3 | 605.00 USD | 100.49% |
| 2014 FY | 126.3 Thousand USD | 208.96% |
| 2014 Q4 | 126.3 Thousand USD | 20777.02% |
| 2013 Q3 | -3653.00 USD | 0.0% |
| 2013 Q4 | -115.92 Thousand USD | -3073.34% |
| 2013 FY | -115.92 Thousand USD | -12459.26% |
| 2013 Q1 | 923.00 USD | 0.0% |
| 2012 FY | -923.00 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 48586.031% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 88.755% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 98.516% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 354.454% |
| Rebus Holdings, Inc. | 305 Thousand USD | -108.251% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 110.075% |
| Qrons Inc. | 351.42 Thousand USD | -80.739% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -2.057% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 98.538% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 3212.343% |
| Skye Bioscience, Inc. | -5.72 Million USD | 111.102% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 95.971% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 84.576% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -58.061% |
| SQZ Biotechnologies Company | -36.23 Million USD | 101.753% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 71.673% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 31.495% |
| Mesoblast Limited | 55.85 Million USD | 98.863% |
| Marizyme, Inc. | 18.56 Million USD | 96.579% |
| Genus plc | 190.6 Million USD | 99.667% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 71.591% |
| Pharming Group N.V. | 109.8 Million USD | 99.422% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 26.164% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 47.675% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 6.593% |
| ContraFect Corporation | -6.02 Million USD | 110.54% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -371.756% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 45.028% |
| IMV Inc. | 7.67 Million USD | 91.719% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 88.455% |
| MultiCell Technologies, Inc. | 90.04 USD | -705327.588% |
| ONE Bio Corp. | 9.04 Million USD | 92.974% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 186.538% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 95.094% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 53.569% |
| Q BioMed Inc. | 4.06 Million USD | 84.356% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 97.921% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 36.97% |
| Biomind Labs Inc. | 711.4 Thousand USD | 10.716% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 98.951% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 68.232% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 95.04% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -76.578% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -354.327% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -3097.096% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 71.155% |
| GB Sciences, Inc. | 1.74 Million USD | 63.649% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 445.598% |
| HST Global, Inc. | 96.79 Thousand USD | -556.212% |
| CSL Limited | 10.52 Billion USD | 99.994% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -208.009% |
| Halberd Corporation | 144.72 Thousand USD | -338.891% |
| Enzolytics Inc. | 981.65 Thousand USD | 35.296% |
| Agentix Corp. | 37.63 Thousand USD | -1587.882% |
| Resverlogix Corp. | 6.45 Million USD | 90.154% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 194.366% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.031% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 101.351% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 91.017% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 76.55% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 107.185% |
| AVAX Technologies, Inc. | -5.9 Million USD | 110.76% |
| Zenith Capital Corp. | 10.06 Thousand USD | -6211.278% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.06% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -216.899% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 73.38% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -286.099% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 3567.447% |
| Kadimastem Ltd | -253.1 Thousand USD | 350.953% |
| Helix BioMedix, Inc. | -2.57 Million USD | 124.714% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 96.867% |
| BioStem Technologies, Inc. | 4.47 Million USD | 85.797% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -215.605% |
| LadRx Corporation | -2.03 Million USD | 131.19% |
| Cell Source, Inc. | 9.23 Million USD | 93.12% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 0.0% |
| NovAccess Global Inc. | 2.17 Million USD | 70.843% |
| Affymax, Inc. | -5.59 Million USD | 111.348% |
| Itoco Inc. | 228.3 Thousand USD | -178.21% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -367.072% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 87.186% |
| Mobile Lads Corp. | 484.23 Thousand USD | -31.17% |
| CytoDyn Inc. | 20.26 Million USD | 96.865% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 98271.097% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 6953.083% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 91.758% |
| SYBLEU INC | 473.71 Thousand USD | -34.082% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 85.749% |
| International Stem Cell Corporation | 2.59 Million USD | 75.476% |
| Bioxytran, Inc. | 1.89 Million USD | 66.551% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -917.684% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 70.876% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 81.504% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 92.574% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 17.789% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 150.813% |
| Neutra Corp. | 52.18 Thousand USD | -1117.098% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 125.519% |
| PureTech Health plc | -167.19 Million USD | 100.38% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 359.349% |
| IXICO plc | -4.44 Million USD | 114.291% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 95.195% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 98.842% |
| CSL Limited | 10.52 Billion USD | 99.994% |
| Cellectis S.A. | -43.81 Million USD | 101.45% |